CalciMedica (NASDAQ:CALC) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

CalciMedica (NASDAQ:CALC) released its earnings results on Wednesday. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02, Zacks reports.

CalciMedica Trading Up 4.0%

NASDAQ CALC opened at $3.34 on Thursday. The company has a current ratio of 5.45, a quick ratio of 5.45 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $48.10 million, a P/E ratio of -2.09 and a beta of 1.37. The business has a fifty day simple moving average of $3.14 and a 200 day simple moving average of $2.56. CalciMedica has a 12 month low of $1.42 and a 12 month high of $4.26.

Insider Buying and Selling at CalciMedica

In related news, insider Sudarshan Hebbar purchased 9,563 shares of the business’s stock in a transaction that occurred on Tuesday, August 19th. The shares were bought at an average cost of $2.82 per share, with a total value of $26,967.66. Following the acquisition, the insider owned 61,539 shares of the company’s stock, valued at $173,539.98. This represents a 18.40% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Eric W. Roberts purchased 9,200 shares of CalciMedica stock in a transaction that occurred on Thursday, August 28th. The shares were bought at an average price of $2.86 per share, with a total value of $26,312.00. Following the transaction, the insider owned 70,107 shares of the company’s stock, valued at $200,506.02. This trade represents a 15.10% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 48,782 shares of company stock worth $140,231. Insiders own 41.55% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CalciMedica stock. Cetera Investment Advisers lifted its stake in shares of CalciMedica Inc. (NASDAQ:CALC) by 33.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,385 shares of the company’s stock after purchasing an additional 9,045 shares during the period. Cetera Investment Advisers owned 0.26% of CalciMedica worth $58,000 at the end of the most recent quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of CalciMedica in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, CalciMedica has an average rating of “Hold” and a consensus price target of $16.00.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.